Compare Humana Inc (HUM) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Procter & Gamble Co — how do they compare? Humana Inc trades at $374.67 (market cap $46.31B), while Procter & Gamble Co trades at $144.82 (market cap $340.39B). The key difference: Procter & Gamble Co is far larger — about 7.4× Humana Inc's market cap, and Procter & Gamble Co pays the higher dividend (2.97%). Which is the better fit depends on your goals.
| HUM | PG | |
|---|---|---|
Market Cap | $46.31B | $340.39B |
Sector | Health | Consumer Staples |
52-Week High | $409.42 | $167.18 |
52-Week Low | $163.67 | $138.10 |
Enterprise Value | $53.67B | $366.23B |
Dividend Yield | 0.92% | 2.97% |
Volume | — | 6,423,436 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $385.00, up 4.82% today, with a bullish technical outlook and analyst consensus price target of $399.53. Recent earnings beats in Q1 and Q2 2026, alongside revenue growth to $129.66 billion in 2025, support fundamentals, though net margins have compressed. The company is expanding its Medicaid business and targeting margin improvements by 2027.
The stock offers upside to consensus targets but faces risks from Medicare Advantage margin pressures and regulatory changes. Profitability trends are weak despite revenue growth, requiring successful cost management to meet 2028 targets. Institutional sentiment is mixed with a majority hold rating.
Procter & Gamble (PG) trades at $144.88, down 0.61% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a net income margin of 18.44% and consistent earnings beats in recent quarters, including Q2 2026 EPS of $1.43 versus $1.41 expected. Revenue reached $84.28 billion in 2025, with a gross profit margin of 50.18%. Recent news highlights PG's dividend reliability and supply chain enhancements, though valuation multiples like a P/E of 22.12 remain elevated compared to peers.
The outlook is cautiously optimistic, supported by analyst consensus favoring Buy ratings (52.83%) and a price target of $161.20, implying potential upside. Risks include premium valuation pressure and soft demand concerns. PG's stable cash flow and 69-year dividend growth history offer defensive appeal in volatile markets, but investors should monitor execution against modest revenue growth projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
